These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 18779478

  • 1. Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial.
    Kim SJ, Lo WR, Hubbard GB, Srivastava SK, Denny JP, Martin DF, Yan J, Bergstrom CS, Cribbs BE, Schwent BJ, Aaberg TM.
    Arch Ophthalmol; 2008 Sep; 126(9):1203-8. PubMed ID: 18779478
    [Abstract] [Full Text] [Related]

  • 2. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.
    Duong HV, Westfield KC, Chalkley TH.
    J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399
    [Abstract] [Full Text] [Related]

  • 3. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
    Trattler W, McDonald M.
    Cornea; 2007 Jul; 26(6):665-9. PubMed ID: 17592313
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation.
    Sandoval HP, De Castro LE, Vroman DT, Solomon KD.
    J Ocul Pharmacol Ther; 2006 Aug; 22(4):251-7. PubMed ID: 16910866
    [Abstract] [Full Text] [Related]

  • 5. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients.
    Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M, Acular LS for Cystoid Macular Edema (ACME) Study Group.
    Am J Ophthalmol; 2008 Oct; 146(4):554-560. PubMed ID: 18599019
    [Abstract] [Full Text] [Related]

  • 6. Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial.
    Ticly FG, Lira RP, Zanetti FR, Machado MC, Rodrigues GB, Arieta CE.
    J Ocul Pharmacol Ther; 2014 Aug; 30(6):495-501. PubMed ID: 24735005
    [Abstract] [Full Text] [Related]

  • 7. Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study.
    Fekrat S, Marsh MJ, Elsing SH, Raja SC, de Juan E, Campochiaro PA, Haller JA.
    Retina; 2003 Feb; 23(1):8-13. PubMed ID: 12652225
    [Abstract] [Full Text] [Related]

  • 8. Role of topical nepafenac in prevention and treatment of macular edema after vitreoretinal surgery.
    Naithani P, Puranik S, Vashisht N, Khanduja S, Kumar S, Garg S.
    Retina; 2012 Feb; 32(2):250-5. PubMed ID: 21926942
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve.
    Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T.
    J Cataract Refract Surg; 2006 Sep; 32(9):1474-82. PubMed ID: 16931258
    [Abstract] [Full Text] [Related]

  • 11. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
    Lindstrom R, Holland E, Lane S, Raizman M, Reilly C.
    Cornea; 2008 Apr; 27(3):385-6; author reply 386-7. PubMed ID: 18362679
    [No Abstract] [Full Text] [Related]

  • 12. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%.
    Schoenberger SD, Kim SJ, Sheng J, Calcutt MW.
    JAMA Ophthalmol; 2014 Feb; 132(2):150-4. PubMed ID: 24264034
    [Abstract] [Full Text] [Related]

  • 13. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
    Toyos R.
    Cornea; 2008 Apr; 27(3):384; author reply 384-5. PubMed ID: 18362678
    [No Abstract] [Full Text] [Related]

  • 14. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification.
    Almeida DR, Khan Z, Xing L, Bakar SN, Rahim K, Urton T, El-Defrawy SR.
    J Cataract Refract Surg; 2012 Sep; 38(9):1537-43. PubMed ID: 22795976
    [Abstract] [Full Text] [Related]

  • 15. The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial.
    Toker MI, Erdem H, Erdogan H, Arici MK, Topalkara A, Arslan OS, Pahsa A.
    Am J Ophthalmol; 2006 May; 141(5):902-905. PubMed ID: 16527227
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients.
    Solomon KD, Donnenfeld ED, Raizman M, Sandoval HP, Stern K, VanDenburgh A, Cheetham JK, Schiffman R, Ketorolac Reformulation Study Groups 1 and 2.
    J Cataract Refract Surg; 2004 Aug; 30(8):1653-60. PubMed ID: 15313287
    [Abstract] [Full Text] [Related]

  • 17. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy.
    Schoenberger SD, Kim SJ, Shah R, Sheng J, Cherney E.
    JAMA Ophthalmol; 2014 Jan; 132(1):32-7. PubMed ID: 24336915
    [Abstract] [Full Text] [Related]

  • 18. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
    Bucci FA, Waterbury LD.
    Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
    [Abstract] [Full Text] [Related]

  • 19. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery.
    Solomon KD, Cheetham JK, DeGryse R, Brint SF, Rosenthal A.
    Ophthalmology; 2001 Feb; 108(2):331-7. PubMed ID: 11158809
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.